Sutro Biopharma, Inc. (STRO) vs Protara Therapeutics, Inc. (TARA)

A side-by-side comparison of Sutro Biopharma, Inc. and Protara Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — STRO vs TARA

growth of $100 · dividends reinvested · last 8y
STRO -90.0% (-25.1%/yr)TARA -96.6% (-34.5%/yr)STRO compounded faster over this window
050100150200Start $1002020202220242026$10$3
STRO TARA

STRO vs TARA: by the numbers

  • •TARA is the larger company ($144M vs $140M market cap).
  • •Both run net losses; TARA's is the smaller (0.00% vs -395.25% net margin).

Metrics side by side

Valuation

MetricSTROTARA
P/S ratio3.06N/A
P/B ratioN/A0.89

Profitability

MetricSTROTARA
Gross margin97.20%0.00%
Operating margin-102.41%0.00%
Net margin-395.25%0.00%
ROEN/A-43.40%
ROIC-100.04%-47.18%

Growth (annualized)

MetricSTROTARA
Revenue CAGR (5Y)19.13%N/A
Total return CAGR (5Y)-39.51%-16.45%

Frequently asked

How have STRO and TARA total returns compared?
Over the past 5 years, STRO delivered -39.51% and TARA delivered -16.45% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.